175 related articles for article (PubMed ID: 9390198)
21. Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma.
Holladay FP; Heitz-Turner T; Bayer WL; Wood GW
J Neurooncol; 1996 Feb; 27(2):179-89. PubMed ID: 8699241
[TBL] [Abstract][Full Text] [Related]
22. Locally superantigen-activated peritoneal cytolytic T lymphocytes belong to the CD8+ CD45RC- subset and lyse MHC class II+ tumor cells.
Hansson J; Ericsson PO; Dohlsten M; Sjögren HO; Kalland T; Hedlund G
Immunol Lett; 1992 Dec; 34(3):229-36. PubMed ID: 1487309
[TBL] [Abstract][Full Text] [Related]
23. Specific adoptive immunotherapy of malignant glioma with long-term cytotoxic T lymphocyte line expanded in T-cell growth factor. Experimental study and future prospects.
Yamasaki T; Handa H; Yamashita J; Watanabe Y; Namba Y; Hanaoka M
Neurosurg Rev; 1984; 7(1):37-54. PubMed ID: 6611523
[TBL] [Abstract][Full Text] [Related]
24. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
25. [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
Nitta T
No To Shinkei; 1992 Jul; 44(7):605-13. PubMed ID: 1419336
[No Abstract] [Full Text] [Related]
26. T cell adoptive immunotherapy of newly diagnosed gliomas.
Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
[TBL] [Abstract][Full Text] [Related]
27. Synergy between interleukin-2 and prothymosin alpha for the increased generation of cytotoxic T lymphocytes against autologous human carcinomas.
Voutsas IF; Baxevanis CN; Gritzapis AD; Missitzis I; Stathopoulos GP; Archodakis G; Banis C; Voelter W; Papamichail M
Cancer Immunol Immunother; 2000 Oct; 49(8):449-58. PubMed ID: 11043852
[TBL] [Abstract][Full Text] [Related]
28. Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
Lazovic J; Jensen MC; Ferkassian E; Aguilar B; Raubitschek A; Jacobs RE
Clin Cancer Res; 2008 Jun; 14(12):3832-9. PubMed ID: 18559603
[TBL] [Abstract][Full Text] [Related]
29. Recurrent malignant glioma in adults.
Tatter SB
Curr Treat Options Oncol; 2002 Dec; 3(6):509-24. PubMed ID: 12392640
[TBL] [Abstract][Full Text] [Related]
30. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.
Thomas C; Schober R; Lenard HG; Lumenta CB; Jacques DB; Wechsler W
Neuropediatrics; 1992 Jun; 23(3):123-5. PubMed ID: 1641079
[TBL] [Abstract][Full Text] [Related]
32. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial.
Merchant RE; McVicar DW; Merchant LH; Young HF
J Neurooncol; 1992 Jan; 12(1):75-83. PubMed ID: 1541981
[TBL] [Abstract][Full Text] [Related]
33. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
Mamelak AN; Rosenfeld S; Bucholz R; Raubitschek A; Nabors LB; Fiveash JB; Shen S; Khazaeli MB; Colcher D; Liu A; Osman M; Guthrie B; Schade-Bijur S; Hablitz DM; Alvarez VL; Gonda MA
J Clin Oncol; 2006 Aug; 24(22):3644-50. PubMed ID: 16877732
[TBL] [Abstract][Full Text] [Related]
34. An experimental approach to specific adoptive immunotherapy for malignant brain tumors.
Yamasaki T; Kikuchi H
Nihon Geka Hokan; 1989 Nov; 58(6):485-92. PubMed ID: 2519184
[TBL] [Abstract][Full Text] [Related]
35. Differentiation of glioma and radiation injury in rats using in vitro produce magnetically labeled cytotoxic T-cells and MRI.
Arbab AS; Janic B; Jafari-Khouzani K; Iskander AS; Kumar S; Varma NR; Knight RA; Soltanian-Zadeh H; Brown SL; Frank JA
PLoS One; 2010 Feb; 5(2):e9365. PubMed ID: 20195476
[TBL] [Abstract][Full Text] [Related]
36. Restoration of cytotoxic T lymphocyte function in malignant pleural effusion: interleukin-15 vs. interleukin-2.
Chen YM; Ting CC; Peng JW; Yang WK; Yang KY; Tsai CM; Perng RP
J Interferon Cytokine Res; 2000 Jan; 20(1):31-9. PubMed ID: 10670650
[TBL] [Abstract][Full Text] [Related]
37. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma.
Kobayashi T; Yamanaka R; Homma J; Tsuchiya N; Yajima N; Yoshida S; Tanaka R
Cancer Immunol Immunother; 2003 Oct; 52(10):632-7. PubMed ID: 12827308
[TBL] [Abstract][Full Text] [Related]
38. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.
Wood GW; Holladay FP; Turner T; Wang YY; Chiga M
J Neurooncol; 2000 Jun; 48(2):113-20. PubMed ID: 11083074
[TBL] [Abstract][Full Text] [Related]
39. Induction of human glioma-specific cytotoxic T-lymphocyte lines by autologous tumor stimulation and interleukin 2.
Miyatake S; Handa H; Yamashita J; Yamasaki T; Ueda M; Namba Y; Hanaoka M
J Neurooncol; 1986; 4(1):55-64. PubMed ID: 3489081
[TBL] [Abstract][Full Text] [Related]
40. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
